| Keywords: |
review; treatment planning; cancer radiotherapy; cancer staging; neoplasm staging; prostate specific antigen; cancer prevention; protein tyrosine kinase; angiogenesis; cancer hormone therapy; prostate cancer; prostate-specific antigen; prostatic neoplasms; disease progression; finasteride; gene therapy; bicalutamide; cancer control; clinical trials; suramin; androstanolone; neoplasms, hormone-dependent; genistein; thapsigargin; beam therapy; herbimycin a; human; male; priority journal; support, u.s. gov't, p.h.s.
|
